IMNM News & Analysis
2 articles
Market Mood
William Blair Initiates Immunome (IMNM) Coverage at Outperform
William Blair has initiated coverage on Immunome (IMNM) with an outperform rating. This suggests that the investment firm expects the biotechnology company to perform better than the average market return. Analysts from William Blair have not provided a specific price target or detailed guidance figures in the initial report. The coverage initiation could boost investor confidence as it indicates potential growth prospects for Immunome. This matters for investors as an outperform rating from a recognized firm can increase visibility and attract new investment to the stock.
Read More: William Blair Initiates Immunome (IMNM) Coverage at Outperform
Immunome (IMNM) Chief Scientist Sells 9,438 Shares for $204,238
Jack Higgins, Chief Scientific Officer of Immunome (IMNM), sold 9,438 shares on April 2, 2026, for $204,238. Post-transaction, Higgins holds 22,000 direct shares and 3,000 indirect shares, having reduced his direct ownership by 30.02%. The share price at market close was $21.84, reflecting a one-year price change of 250%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating routine liquidity management rather than market speculation.
Read More: Immunome (IMNM) Chief Scientist Sells 9,438 Shares for $204,238